(Q51832506)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

Clarisa Beatriz Palatnik-de-Sousa

20 December 2019

main subject

visceral leishmaniasis

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Wania Renata Santos

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Ivan Augusto Aguiar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Edilma Paraguai de Souza

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Valéria M F de Lima

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Marcos Palatnik

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

English

0 references

publication date

1 December 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

4668-4676

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Leishmania infantum infection rates in Phlebotomus perniciosus fed on naturally infected dogs under antimonial treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Studies on canine leishmaniasis control. 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Canine leishmaniasis transmission: higher infectivity amongst naturally infected dogs to sand flies is associated with lower proportions of T helper cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Leishmania donovani surface glycoconjugate GP36 is the major immunogen component of the Fucose-Mannose Ligand (FML)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

A new approach to the phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Vaccination of Swiss Albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Leishmania donovani: titration of antibodies to the fucose-mannose ligand as an aid in diagnosis and prognosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

The FML (Fucose Mannose Ligand) of Leishmania donovani. a new tool in diagnosis, prognosis, transfusional control and vaccination against human kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Vaccination of dogs against Babesia canis infection using parasite antigens from in vitro culture

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Practical progress and new drugs for changing patterns of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Treatment of cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Recent advances in the fight against leishmaniasis with natural products

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Therapy of murine cutaneous leishmaniasis by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Early in vitro priming of distinct T(h) cell subsets determines polarized growth of visceralizing Leishmania in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2803%2900527-9

7 January 2021

10.1016/S0264-410X(03)00527-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14585674%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference